Cipla targets South African asthma market with breath activated inhaler
Cipla has launched a breath activated inhaler in South Africa.
The product – known as Synchrobreathe – delivery a dose when the user inhalers, which will help sufferers of obstructive airway diseases – asthma and COPD, for example – manage their diseases more effectively according to Cipla Medpro CEO, Paul Miller.
“Incorrect use of inhalers and non-adherence to treatment are major contributors to the poor levels of asthma control we experience in South Africa” Miller said.
South Africa has one of the highest asthma death rates in the world. According to a 2014 study by the Global Asthma Network around 15,000 people die from the disease each year.